Mizuho Securities upgrades Relmada Therapeutics (RLMD) to a Buy

Tip Ranks
2025.11.19 09:35
portai
I'm PortAI, I can summarize articles.

Mizuho Securities analyst Uy Ear upgraded Relmada Therapeutics (RLMD) to a Buy with a price target of $10.00. Despite a general Hold consensus, Ear focuses on the Healthcare sector and has an average return of -1.3% with a 37.82% success rate on stock recommendations.

Mizuho Securities analyst Uy Ear upgraded Relmada Therapeutics to a Buy today and set a price target of $10.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Ear covers the Healthcare sector, focusing on stocks such as Tectonic Therapeutic, Sarepta Therapeutics, and Alkermes. According to TipRanks, Ear has an average return of -1.3% and a 37.82% success rate on recommended stocks.

The word on The Street in general, suggests a Hold analyst consensus rating for Relmada Therapeutics.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer